

Cliona C Kirwan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3221571/publications.pdf>

Version: 2024-02-01

59
papers

1,986
citations

430442

18
h-index

253896

43
g-index

61
all docs

61
docs citations

61
times ranked

3067
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2022, 75, 69-76.	0.5	9
2	Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. <i>Breast</i> , 2022, 61, 145-155.	0.9	12
3	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). <i>BMJ Open</i> , 2022, 12, e058050.	0.8	4
4	The MARECA (national study of management of breast cancer locoregional recurrence and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 To decision making. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1510-1519.	0.5	5
5	No association between breast pain and breast cancer: a prospective cohort study of 10 830 symptomatic women presenting to a breast cancer diagnostic clinic. <i>British Journal of General Practice</i> , 2022, 72, e234-e243.	0.7	8
6	Contemporary breast cancer treatment-associated thrombosis. <i>Thrombosis Research</i> , 2022, 213, S8-S15.	0.8	2
7	Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2350-2365.	1.9	18
8	A Novel Mixed-Methods Platform Study Protocol for Investigating New Surgical Devices, with Embedded Shared Learning: Ibra-net Breast Lesion Localisation Study. <i>International Journal of Surgery Protocols</i> , 2021, 25, 26-33.	0.5	5
9	Patient and public priorities for breast cancer research: a qualitative study in the UK. <i>BMJ Open</i> , 2021, 11, e036072.	0.8	6
10	The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. <i>Scientific Reports</i> , 2021, 11, 2847.	1.6	20
11	Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 4Alert Level phase of the B-MaP-C study. <i>British Journal of Cancer</i> , 2021, 124, 1785-1794.	2.9	21
12	Innovations for the future of breast surgery. <i>British Journal of Surgery</i> , 2021, 108, 908-916.	0.1	10
13	Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design. <i>Trials</i> , 2021, 22, 397.	0.7	4
14	Update on the role of circulating tumour cells in cancer-associated thrombosis. <i>Thrombosis Update</i> , 2021, 5, 100066.	0.4	1
15	Risk factors for complications and implant loss after prepectoral implant-based immediate breast reconstruction: medium-term outcomes in a prospective cohort. <i>British Journal of Surgery</i> , 2021, 108, 534-541.	0.1	11
16	The Effects of Ionising and Non-Ionising Electromagnetic Radiation on Extracellular Matrix Proteins. <i>Cells</i> , 2021, 10, 3041.	1.8	20
17	BROWSE: A multicentre comparison of nine year outcomes in acellular dermal matrix based and complete submuscular implant-based immediate breast reconstruction-aesthetics, capsular contracture and patient reported outcomes. <i>European Journal of Surgical Oncology</i> , 2021, , .	0.5	5
18	Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 870-877.	1.2	17

#	ARTICLE	IF	CITATIONS
19	The B-MaP-C study: Breast cancer management pathways during the COVID-19 pandemic. Study protocol. International Journal of Surgery Protocols, 2020, 24, 1-5.	0.5	9
20	Rivaroxaban compared to no treatment in ER-negative stage Iâ€“III early breast cancer patients (the TIP) Tj ETQq0 0 0 rgBT /Overlock 10 controlled trial. Trials, 2020, 21, 749.	0.7	5
21	Breast cancer stromal clotting activation (Tissue Factor and thrombin): A preâ€“invasive phenomena that is prognostic in invasion. Cancer Medicine, 2020, 9, 1768-1778.	1.3	20
22	Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet, The, 2020, 395, 1613-1626.	6.3	603
23	A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2â€“ Primary Breast Cancer. Clinical Cancer Research, 2020, 26, 4242-4249.	3.2	29
24	Comparing long-term local recurrence rates of surgical and non-surgical management of close anterior margins in breast conserving surgery. Breast Cancer Research and Treatment, 2019, 176, 311-319.	1.1	7
25	Is breast seroma after tumour resection associated with patient-reported breast appearance change following radiotherapy? Results from the IMPORT HIGH (CRUK/06/003) trial. Radiotherapy and Oncology, 2019, 136, 190-196.	0.3	8
26	Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 305-317.	0.8	58
27	Clinical management of idiopathic mastalgia: a systematic review. Journal of Primary Health Care, 2018, 10, 312.	0.2	34
28	Opportunities and priorities for breast surgical research. Lancet Oncology, The, 2018, 19, e521-e533.	5.1	36
29	Prepectoral Implant-Based Breast Reconstruction. Plastic and Reconstructive Surgery - Global Open, 2017, 5, e1488.	0.3	75
30	Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis. BMC Cancer, 2017, 17, 747.	1.1	28
31	Tissue Factor promotes breast cancer stem cell activity <i>in vitro</i> . Oncotarget, 2017, 8, 25915-25927.	0.8	16
32	Challenges in enumeration of CTCs in breast cancer using techniques independent of cytokeratin expression. PLoS ONE, 2017, 12, e0175647.	1.1	12
33	Improving accuracy of clinical coding in surgery: collaboration is key. Journal of Surgical Research, 2016, 204, 490-495.	0.8	31
34	OC-09 - Microparticle-mediated transfer of TF hypercoagulability between cancer cells. Thrombosis Research, 2016, 140, S172.	0.8	2
35	PO-50 - The effect of tissue factor expression on colorectal cancer cell proliferation. Thrombosis Research, 2016, 140, S195.	0.8	2
36	PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology. Thrombosis Research, 2016, 140, S189-S190.	0.8	6

#	ARTICLE	IF	CITATIONS
37	PO-52 - Effect of tissue factor expression by colorectal cancer on cancer stem cell activity. <i>Thrombosis Research</i> , 2016, 140, S195-S196.	0.8	1
38	PO-31 - Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer. <i>Thrombosis Research</i> , 2016, 140, S188.	0.8	2
39	PO-32 - Patient, tumour and operative factors influencing perioperative hypercoagulability in colorectal cancer. <i>Thrombosis Research</i> , 2016, 140, S188.	0.8	1
40	When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. <i>Blood</i> , 2016, 127, 849-857.	0.6	93
41	It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence. <i>Clinical Oncology</i> , 2016, 28, 594-596.	0.6	63
42	PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion. <i>Thrombosis Research</i> , 2016, 140, S184.	0.8	3
43	PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation. <i>Thrombosis Research</i> , 2016, 140, S180.	0.8	7
44	PO-09 - Incidence of pre-operative and post-operative deep vein thrombosis in colorectal cancer surgery. Interim results of a prospective clinical study. <i>Thrombosis Research</i> , 2016, 140, S179-S180.	0.8	6
45	PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer. <i>Thrombosis Research</i> , 2016, 140, S195.	0.8	6
46	Increased peri-ductal collagen micro-organization may contribute to raised mammographic density. <i>Breast Cancer Research</i> , 2016, 18, 5.	2.2	98
47	Clinical and radiological presentation of pleomorphic lobular carcinoma in-situ and its association with invasive malignancy. <i>Cancer Treatment Communications</i> , 2015, 4, 113-116.	0.4	0
48	The use of isotope injections in sentinel node biopsy for breast cancer: are the 1- and 2-day protocols equally effective?. <i>SpringerPlus</i> , 2015, 4, 495.	1.2	2
49	Current attitudes to breast reconstruction surgery for women at risk of post-mastectomy radiotherapy: A survey of UK breast surgeons. <i>Breast</i> , 2015, 24, 502-512.	0.9	31
50	Investigation of Proposed Mechanisms of Chemotherapy-Induced Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 420-427.	0.7	30
51	Tumour bed clip localisation for targeted breast radiotherapy: Compliance is proportional to trial-related research activity. <i>European Journal of Surgical Oncology</i> , 2014, 40, 158-162.	0.5	7
52	The significance of circulating tumour cells in breast cancer: A review. <i>Breast</i> , 2014, 23, 552-560.	0.9	37
53	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	2.2	320
54	Orbital Metastases as the Primary Presentation of Lobular Breast Cancer. <i>Breast Journal</i> , 2013, 19, 333-334.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome. <i>Anticancer Research</i> , 2011, 31, 2383-8.	0.5	14
56	Platelet release of Vascular Endothelial Growth Factor (VEGF) in patients undergoing chemotherapy for breast cancer. <i>Journal of Angiogenesis Research</i> , 2009, 1, 7.	2.9	4
57	Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. <i>British Journal of Cancer</i> , 2008, 99, 1000-1006.	2.9	48
58	Current UK practice of thromboprophylaxis for breast surgery. <i>British Journal of Surgery</i> , 2006, 93, 1224-1225.	0.1	6
59	Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. <i>BMJ: British Medical Journal</i> , 2003, 327, 597-598.	2.4	40